Resources

October 20, 2023

Scientific Poster: Enhancing AAV6 Vector Production for Cell Therapies: Harnessing the Potential of Viralgen's Pro10™ Platform for Scalable Manufacturing

Viralgen leverages its Pro10™ production platform to manufacture high-quality AAV6 vectors, enabling efficient, large-scale production for cell therapies. With broad tropism, high transduction efficiency, and scalability, AAV6 offers immense potential in cell therapy advancements.

Download

Explore more

Insights

Viralgen Vector Core and Elpida Therapeutics partner to manufacture gene therapy medicines for anticipated Spastic Paraplegia 50 (SPG50) and Charcot-Marie-Tooth disease type 4J (CMT4J) clinical trials

Viralgen Vector Core and Elpida Therapeutics partner to manufacture gene therapy medicines for anticipated Spastic Paraplegia 50 (SPG50) and Charcot-Marie-Tooth disease type 4J (CMT4J) clinical trials Trial participants with Spastic Paraplegia 50...

September 29, 2023

Insights

Successful meeting at the ASGCT 2023

Last week, we participated in the ASGCT 26th Annual Meeting, which was held in Los Angeles. We are grateful for a successful meeting at ASGCT and would like to thank all our booth visitors, customers who took time out to meet with the team, and...

Resources

Scientific Poster: Enhancing AAV6 Vector Production for Cell Therapies: Harnessing the Potential of Viralgen's Pro10™ Platform for Scalable Manufacturing

VIRALGEN BUILDING 1

VIRALGEN BUILDING 2

WHO WE ARE

WHAT WE DO

EXPERT INSIGHTS

CAREERS

CONTACT US

Policies